Lam Research (LRCX) delivered mixed results in Q4 FY2026 on revenue of $6.7B versus the $6.7B estimate (+30.0% YoY) and EPS of $1.82. The next Lam Research (LRCX) earnings date is Oct 21, 2026. Below is the full Lam Research earnings breakdown — the risk-adjusted verdict, price forecast, technicals, options and hedge-fund 13F holdings, decoded in plain English.
Lam Research (LRCX) Earnings Analysis — key stats
Next earnings date
Oct 21, 2026
Latest reported quarter
Q4 FY2026
Earnings verdict
Mixed
EPS beat rate
8 of last 8 (quarters above estimate)
Avg next-day move
±5.7% (over the last 8 reports)
Post-earnings direction
Up 7 / Down 1 (of the last 8 reports)
Implied move (next report)
±36.2% (options-derived · into Oct 21, 2026)
Institutional ownership
152.0% (13F as of 2026-06-30)
Top 10 holders
41.7% (of shares outstanding)
Insider activity
2 buys / 10 sells (recent Form 4 filings)
Revenue
$6.7B (vs $6.7B est · +0.9% surprise · +30.0% YoY)
EPS
$1.82 (vs $1.69 est · +7.7% surprise · +34.8% YoY)
Share price
$310.17 (-1.2%)
Market cap
$387.9B
Lam Research (LRCX) Earnings Analysis — beat / miss history
Quarter
Revenue
EPS
EPS surprise
Next-day move
Verdict
Q1 FY2027
$6.7B vs $6.7B est
$1.82 vs $1.69 est
+7.7%
+10.4%
Mixed
Q4 FY2026
$5.8B vs $5.8B est
$1.47 vs $1.36 est
+8.1%
+0.1%
Mixed
Q3 FY2026
$5.3B vs $5.2B est
$1.27 vs $1.17 est
+8.5%
+4.1%
Beat
Q2 FY2026
$5.3B vs $5.2B est
$1.26 vs $1.22 est
+3.3%
+1.7%
Mixed
Q1 FY2026
$5.2B vs $5.0B est
$1.33 vs $1.21 est
+9.9%
-4.1%
Beat
Q4 FY2025
$4.7B vs $4.6B est
$1.04 vs $1.00 est
+4.0%
+11.7%
Mixed
Q3 FY2025
$4.4B vs $4.3B est
$0.91 vs $0.88 est
+3.6%
+8.3%
Mixed
Q2 FY2025
$4.2B vs $4.1B est
$0.86 vs $0.81 est
+6.2%
+4.9%
Beat
Top institutional holders
Holder
% outstanding
Shares
Value
QoQ change
Blackrock, INC.
10.6%
132.7M
$57.5B
-0.1%
Vanguard Capital Management LLC
6.5%
81.7M
$35.4B
+0.7%
State Street Corp
4.9%
60.7M
$26.3B
+2.6%
Invesco Ltd.
4.2%
52.3M
$22.7B
+99.6%
Jpmorgan Chase & CO
3.6%
45.3M
$18.6B
+38.5%
Vanguard Portfolio Management LLC
2.9%
36.6M
$15.9B
-1.1%
Geode Capital Management, LLC
2.8%
34.5M
$14.9B
-1.9%
Fmr LLC
2.7%
33.7M
$14.6B
+0.3%
Price T Rowe Associates INC /Md/
2.0%
24.6M
$10.7B
+85.8%
Morgan Stanley
1.5%
19.2M
$8.3B
+1.3%
Recent insider transactions
Insider
Role
Date
Type
Shares
Value
ARCHER TIMOTHY
officer: President and CEO
2026-08-06
Buy
30K
$900990
ARCHER TIMOTHY
officer: President and CEO
2026-08-06
Sell
30K
$9.0M
ARCHER TIMOTHY
officer: President and CEO
2026-08-06
Sell
30K
$900990
Harter Ava
officer: Chief Legal Officer
2026-08-05
Sell
6K
$1.8M
TALWALKAR ABHIJIT Y
director
2026-07-13
Sell
18K
$6.1M
ARCHER TIMOTHY
officer: President and CEO
2026-07-02
Buy
30K
$900990
ARCHER TIMOTHY
officer: President and CEO
2026-07-02
Sell
30K
$11.7M
ARCHER TIMOTHY
officer: President and CEO
2026-07-02
Sell
30K
$900990
What you'll find
Next Lam Research (LRCX) earnings date, the expected move and the estimates priced in
A clear Beat / Miss / In-line / Mixed verdict the moment Lam Research reports
Revenue & EPS versus estimates, guidance and segment trends
Multi-lens price forecast — analyst, quant, technical and options views
Deep research: red flags, risk decoder and earnings-call sentiment
Technicals, options / implied volatility and unusual-activity signals
Hedge-fund and legendary-investor 13F holdings in Lam Research (LRCX)
Side-by-side peer and historical earnings comparison
Frequently asked questions
When is Lam Research's next earnings date?
Lam Research's (LRCX) next scheduled earnings date is Oct 21, 2026. Magnisto shows the confirmed date, the options-implied expected move and the revenue and EPS estimates Wall Street is modeling into the report.
Did Lam Research (LRCX) beat or miss earnings?
In Q4 FY2026, Lam Research (LRCX) posted mixed results — revenue of $6.7B versus the $6.7B estimate (+0.9% surprise) and EPS of $1.82 versus $1.69 expected (+7.7% surprise). Magnisto decodes every Lam Research (LRCX) report into a clear Beat, Miss, In-line or Mixed verdict and checks whether guidance was raised, held or cut.
How often does Lam Research beat earnings estimates?
Over its last 8 reported quarters, Lam Research (LRCX) beat Wall Street EPS estimates 8 times, most recently a mixed result in Q1 FY2027. Magnisto tracks every Lam Research (LRCX) quarter's revenue and EPS versus consensus and grades each one Beat, Miss, In-line or Mixed at a unified ±2% threshold.
How much does Lam Research stock move after earnings?
Over its last 8 quarterly reports, Lam Research (LRCX) moved an average of ±5.7% the day after earnings — ranging from -4.1% (Q1 FY2026) to +11.7% (Q4 FY2025). The stock rose after 7 of those 8 reports and fell after 1. Heading into its next report on Oct 21, 2026, options-implied volatility is pricing in a move of roughly ±36.2% (derived). Magnisto tracks the realized post-earnings move for every Lam Research (LRCX) quarter alongside the beat/miss verdict — past moves don't predict the next one.
Who are the largest shareholders of Lam Research?
Institutions hold about 152.0% of Lam Research's (LRCX) shares outstanding as of the 2026-06-30 13F quarter. Its largest institutional holders include Blackrock, INC. (10.6%), Vanguard Capital Management LLC (6.5%), State Street Corp (4.9%). Magnisto lists Lam Research's (LRCX) top 13F holders with each stake size and its quarter-over-quarter change.
Are insiders buying or selling Lam Research (LRCX)?
In the most recent Form 4 filings Magnisto tracks, Lam Research (LRCX) insiders recorded 2 purchases and 10 sales — net selling. Insider transactions are one signal among many and are often routine (option exercises or scheduled 10b5-1 sales), so Magnisto shows the raw feed for you to judge.
What is the forecast for Lam Research (LRCX) stock?
Magnisto blends analyst price targets, quantitative research, technical trend and options-implied moves into a scenario range for Lam Research (LRCX), anchored to the current $310.17 share price, so you can weigh the bull, base and bear cases for Lam Research side by side.
Is Lam Research (LRCX) a buy right now?
Magnisto does not give buy or sell tips. It gives you the institutional-grade evidence — the verdict, valuation, risks, technicals and hedge-fund 13F flows — so you can decide whether Lam Research fits your own thesis and risk profile. This is research, not investment advice.